INTERIM REPORT JANUARY–JUNE 2009

CONTINUED FOCUS ON CORE PROJECTS

The period January-June in brief
• Net sales amounted to MSEK 4.4 (7.2), whereof the second quarter MSEK 2.2 (5.5)

• Net loss decreased to MSEK 82.7 (101.8), whereof the second quarter MSEK 36.8 (49.9)

• Loss per share decreased to SEK 0.71 (0.88), whereof the second quarter SEK 0.32 (0.43)

• Cash flow from operating activities amounted to MSEK -79.6 (-105.7), whereof the second quarter MSEK -38.6 (-49.7)

• Cash and cash equivalents and other short-term investments totaled MSEK 156.3 (329.2) at the end of the period

• At The Annual American College of Cardiology Meeting in Orlando, Florida, March 29, 2009, results from Karo Bio’s phase IIb study with eprotirome as add-on to statin treatment were presented

• In March, positive results from the phase I program with KB3305 were reported. In addition to healthy volunteers, a group of type 2 diabetes patients was included in the trials

• The collaborative effort with Zydus Cadila have made several breakthroughs that increase the possibilities of finding suitable substances for further development into candidate drugs

For further information, please contact:
Per Olof Wallström, President, tel. +46 8 608 60 20
Erika Söderberg Johnson, Chief Financial Officer, tel. +46 8 608 60 52